MED8

Across TCGA pan-cancer cohorts, MED8 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED8 data layer compared with 24 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MED8 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MED8 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where MED8 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	1.000	0.536	<.001	42	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
LUAD	OS	Quartile	II,III,IV	0.868	0.303	.017	6	view →
OV	DFS	Median	All	0.868	1.000	.040	4	view →
HNSC	OS	Quartile	All	0.786	0.919	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED8–LSCC (OS)

Open the LSCC breakdown →